Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs MEDI 8968 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 13 Oct 2009 Additional trial location (Estonia) identified as reported by ClinicalTrials.gov.
- 13 Oct 2009 Additional trial location (Estonia) identified as reported by ClinicalTrials.gov.
- 11 Jun 2009 Results presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR) 2009.